Product
Quadrivalent Influenza Vaccine
Aliases
VaxigripTetra®
15 clinical trials
11 indications
Indication
Influenza ImmunizationIndication
InfluenzaIndication
Seasonal InfluenzaIndication
Healthy Control ParticipantsIndication
HumanIndication
COVID-19Indication
CancerIndication
ObesityIndication
immune responseIndication
SafetyClinical trial
Immunogenicity and Safety of a Quadrivalent Influenza Vaccine in Participants Aged Above 3 YearsStatus: Completed, Estimated PCD: 2019-10-08
Clinical trial
Enhanced Passive Safety Surveillance of VaxigripTetra® (Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) and Efluelda® (High Dose Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) Vaccines in Europe During the Influenza Season 2023/24Status: Completed, Estimated PCD: 2023-12-15
Clinical trial
Enhanced Passive Safety Surveillance of VaxigripTetra® (Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) and Efluelda® (High-dose Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) Vaccines in Europe During the Influenza Season 2022/23.Status: Completed, Estimated PCD: 2022-11-29
Clinical trial
Enhanced Passive Safety Surveillance of VaxigripTetra® (Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) and Efluelda® (Quadrivalent Inactivated Split Virion Influenza Vaccine, Intramuscular Route) Vaccines in Europe During the Influenza Season 2021/22.Status: Completed, Estimated PCD: 2021-12-02
Clinical trial
Immunogenicity and Safety of High-Dose Quadrivalent Influenza Vaccine (SP0178) Administered by Intramuscular Route Versus Standard-Dose Quadrivalent Influenza Vaccine by Subcutaneous Route in Subjects 60 Years of Age and Older in JapanStatus: Completed, Estimated PCD: 2021-01-14
Clinical trial
A Randomized, Double-blind Clinical Trial to Evaluate Lot-to-lot Consistency , Immunogenicity and Safety of Quadrivalent Influenza Vaccine (Split Virion), Inactivated in Health Populations Aged 9~59 Years OldStatus: Completed, Estimated PCD: 2023-01-24
Clinical trial
Immunogenicity and Safety of the Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of AgeStatus: Completed, Estimated PCD: 2020-12-01
Clinical trial
Investigating Uptake and Subsequent Health Outcomes Associated With Pfizer-BioNTech Bivalent COVID-19/Influenza Vaccine Concomitant Administration Using a Claims-based Real-world Data Source in the USStatus: Completed, Estimated PCD: 2023-05-12
Clinical trial
Relative Effectiveness of a High-Dose Quadrivalent Influenza Vaccine Versus a Standard-Dose Quadrivalent Influenza Vaccine in Subjects 65 Years of Age and OlderStatus: Terminated, Estimated PCD: 2020-05-31
Clinical trial
Immunogenicity and Safety of Quadrivalent Influenza Vaccine In 6 to 35 Months Population: a Randomized, Double-blind, Parallel-group Ⅱ Phase of Clinical TrialsStatus: Completed, Estimated PCD: 2021-09-14
Clinical trial
Comparison of High vs. Standard Dose Flu Vaccine in Pediatric Stem Cell Transplant RecipientsStatus: Active (not recruiting), Estimated PCD: 2021-12-01
Clinical trial
A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MODIFIED RNA VACCINES AGAINST INFLUENZA IN HEALTHY ADULTSStatus: Recruiting, Estimated PCD: 2025-02-05
Clinical trial
Optimising Protection for Pregnant Women and Infants With Maternal VaccinationStatus: Active (not recruiting), Estimated PCD: 2023-09-29
Clinical trial
A Blind Randomized Clinical Trial, With Active Controls, to Evaluate the Immunogenicity and Safety of the Quadrivalent Influenza Vaccine (Split Virion, Inactivated) From Instituto Butantan, in Infants and Children Aged 6 to 35 Months.Status: Recruiting, Estimated PCD: 2024-03-15
Clinical trial
Immunogenicity and Safety of Concomitant Administration of Omicron-containing Bivalent COVID-19 Vaccines With Seasonal Influenza VaccinesStatus: Completed, Estimated PCD: 2022-12-15